July 9, 2020 Hong Kong – Davis Polk Advises Shenzhen Hepalink Pharmaceutical Group Co., Ltd. On Its HK$4.05 Billion ($523 Million) Initial Public Offering.
July 8, 2020 Non-Resident Employment Visa Requirement For Arbitral Proceedings In Hong Kong Lifted In New Scheme.
